294 related articles for article (PubMed ID: 17008548)
1. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors.
Payne SG; Oskeritzian CA; Griffiths R; Subramanian P; Barbour SE; Chalfant CE; Milstien S; Spiegel S
Blood; 2007 Feb; 109(3):1077-85. PubMed ID: 17008548
[TBL] [Abstract][Full Text] [Related]
2. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
Chiba K
Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
[TBL] [Abstract][Full Text] [Related]
3. Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720.
Kihara A; Igarashi Y
Biochim Biophys Acta; 2008 Sep; 1781(9):496-502. PubMed ID: 18555808
[TBL] [Abstract][Full Text] [Related]
4. FTY720 suppresses interleukin-1beta-induced secretory phospholipase A2 expression in renal mesangial cells by a transcriptional mechanism.
Xin C; Ren S; Eberhardt W; Pfeilschifter J; Huwiler A
Br J Pharmacol; 2007 Apr; 150(7):943-50. PubMed ID: 17325654
[TBL] [Abstract][Full Text] [Related]
5. [A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Chiba K
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr; 32(2):92-101. PubMed ID: 19404007
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of the immunomodulator FTY720 inhibits programmed cell death of fibroblasts via the S1P3 receptor subtype and Bcl-2 activation.
Potteck H; Nieuwenhuis B; Lüth A; van der Giet M; Kleuser B
Cell Physiol Biochem; 2010; 26(1):67-78. PubMed ID: 20502006
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells.
Butler J; Lana D; Round O; LaMontagne K
Prostaglandins Other Lipid Mediat; 2004 Jan; 73(1-2):29-45. PubMed ID: 15165029
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor.
Oo ML; Thangada S; Wu MT; Liu CH; Macdonald TL; Lynch KR; Lin CY; Hla T
J Biol Chem; 2007 Mar; 282(12):9082-9. PubMed ID: 17237497
[TBL] [Abstract][Full Text] [Related]
9. [New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Chiba K
Yakugaku Zasshi; 2009 Jun; 129(6):655-65. PubMed ID: 19483408
[TBL] [Abstract][Full Text] [Related]
10. Antinociceptive activity of the S1P-receptor agonist FTY720.
Coste O; Pierre S; Marian C; Brenneis C; Angioni C; Schmidt H; Popp L; Geisslinger G; Scholich K
J Cell Mol Med; 2008 Jun; 12(3):995-1004. PubMed ID: 18494940
[TBL] [Abstract][Full Text] [Related]
11. Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2.
Yoshino T; Tabunoki H; Sugiyama S; Ishii K; Kim SU; Satoh J
Cell Mol Neurobiol; 2011 Oct; 31(7):1009-20. PubMed ID: 21519925
[TBL] [Abstract][Full Text] [Related]
12. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.
Chiba K; Matsuyuki H; Maeda Y; Sugahara K
Cell Mol Immunol; 2006 Feb; 3(1):11-9. PubMed ID: 16549044
[TBL] [Abstract][Full Text] [Related]
13. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.
Brinkmann V; Cyster JG; Hla T
Am J Transplant; 2004 Jul; 4(7):1019-25. PubMed ID: 15196057
[TBL] [Abstract][Full Text] [Related]
14. The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720.
Hisano Y; Kobayashi N; Kawahara A; Yamaguchi A; Nishi T
J Biol Chem; 2011 Jan; 286(3):1758-66. PubMed ID: 21084291
[TBL] [Abstract][Full Text] [Related]
15. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy.
Sensken SC; Bode C; Gräler MH
J Pharmacol Exp Ther; 2009 Mar; 328(3):963-9. PubMed ID: 19074680
[TBL] [Abstract][Full Text] [Related]
17. FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes.
Honig SM; Fu S; Mao X; Yopp A; Gunn MD; Randolph GJ; Bromberg JS
J Clin Invest; 2003 Mar; 111(5):627-37. PubMed ID: 12618517
[TBL] [Abstract][Full Text] [Related]
18. FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
Ntranos A; Hall O; Robinson DP; Grishkan IV; Schott JT; Tosi DM; Klein SL; Calabresi PA; Gocke AR
J Neuroimmunol; 2014 May; 270(1-2):13-21. PubMed ID: 24680062
[TBL] [Abstract][Full Text] [Related]
19. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1.
Schmid G; Guba M; Ischenko I; Papyan A; Joka M; Schrepfer S; Bruns CJ; Jauch KW; Heeschen C; Graeb C
J Cell Biochem; 2007 May; 101(1):259-70. PubMed ID: 17203465
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
Chun J; Hartung HP
Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]